AMLN - comments?

[New-born baby]

Jiesen

Jiesen, Here's a look at AMLN today.
You call that a shoulder~head~shoulder?


I thought so.

Can't seem to bust the $20.00 resistance today. If that's a s~h~s, then Dow Theory says we're looking at $16.70 here before too long.

[New-born baby]

Hang on

Well, good job guys! Maybe I'll get back in at the appropriate point.

Its appropriate now.

[New-born baby]

The next GooG!

My long-term target for AMLN is $200.

Jiesen:
If that happens, we'll be daytrading it like GooG!
Thanks for the targets.

Well, good job guys! Maybe I'll get back in at the appropriate point.

[jiesen]

Can you give me a price target for AMLN for the next 12 months?

Sure. I'd expect to see $40 within 6-12 months. The real growth, though, probably won't happen for another 3-4 years, as that's when the profits will finally start showing up in full force. To be safe though, I will probably take some early profits as they come (around $50 or so). Despite excellent sales, they could still botch it up by mismanaging the money they make. Companies have been known to do that!

My long-term target for AMLN is $200.

[New-born baby]

Price Target

No kidding that AMLN is going to be a blockbuster! Just look at the projection this guy is making for sales this year. (looks much better with yesterday's updated data) We'll easily see $50-100M in sales this year, which was half-over with almost no sales to begin with.

Next year, who knows? $300M, $400M? One thing's for sure, if sales keep up like this, the stock has only one way to go- up!

Can you give me a price target for AMLN for the next 12 months?

[jiesen]

http://members.cox.net/mystock/Amylin.htm

No kidding that AMLN is going to be a blockbuster! Just look at the projection this guy is making for sales this year. (looks much better with yesterday's updated data) We'll easily see $50-100M in sales this year, which was half-over with almost no sales to begin with.

Next year, who knows? $300M, $400M? One thing's for sure, if sales keep up like this, the stock has only one way to go- up!

[New-born baby]

Do it!

You're welcome. Now I'll see if I can do anything to boost that multi-trillion dollar housing market a little for ya.

Yeah, Jiesen. DO IT!

Thinking about selling some $90 or $ 95 covered calls on KBH.

[jiesen]

Nice post, Jiesen. Thank you!

You're welcome. Now I'll see if I can do anything to boost that multi-trillion dollar housing market a little for ya.

[New-born baby]

Thanks Jiesen

Nice post, Jiesen. Thank you!

[jiesen]

Forbes, today, on AMLN:

http://www.forbes.com/markets/2005/08/01/amylin-pharmaceuticals-earnings-0801markets12.html

Amylin's Byetta Still Has Blockbuster Potential

Morgan Stanley maintained an "overweight" rating on Amylin Pharmaceuticals (nasdaq: AMLN - news - people ) ahead of second-quarter results and said the biotech firm's diabetes drug Byetta will likely drive shares higher. "We believe that the Byetta franchise will emerge as a winner, driving significant stock performance over the next 12 to 24 months," said Morgan Stanley. "We continue to believe that Byetta has blockbuster potential."

The research firm predicted second-half volatility in the stock which will come as a result of a number of events including a U.S. Food and Drug Administration panel on Exubera, an inhalable form of insulin made by Pfizer (nyse: PFE - news - people ) and Nektar Therapeutics (nasdaq: NKTR - news - people ). "While we expect significant volatility with the stock as we move through the rest of the year, we recommend using this volatility to buy the stock," the firm said. Byetta, co-marketed with Eli Lilly (nyse: LLY - news - people ), was approved by the FDA in April and launched in June.

Morgan Stanley has a $29 price target on Amylin shares. "We expect commercial uptake of Byetta to be the primary driver of the stock over the next twelve months, and expect investors to follow prescription trends closely. The official sales force launch of Byetta has yet to occur (we understand that the companies have an offsite with the sales force within the next several weeks)," it said. "Additionally, we expect to see acceleration in growth as we move through the third quarter, as patients and physicians return from vacations and as we see prescriptions from post-ADA." The annual American Diabetes Association meeting was held in mid-June.

[jiesen]

New AMLN prescription data

Weekly, ending July 22:
Byetta total 3877, new 3656. Symlin total 1132, new 925

This is not 100% verified, but probably correct. It's at least 10% over what was projected for the week based on daily script #'s. Definitely a reason for AMLN to be up 10% (or more) today.

[spikefader]

Well this is strange. The daily has pulled a fast one. The price action today has changed the characteristics of the channel. What WAS a channel long intraday, by close, it isn't one, and the channel expands, opening the door for bears You got your double bottom at 19.10 today I was happy to note, and price responded well, and now this......but it's a clear bullish candle that one today.

But based on all the other charts, I'm still seeing it favors lower. But hey, you've picked bottoms well in the past, and I'm sure you will in the future!

[jiesen]

fwiw

short interest up huge according to the new figures available today:

http://www.nasdaqtrader.com/asp/short_interest_resp.asp?symbol=amln&SettlementDate=07%2F15%2F2005

26M short now vs. 14M in June.

All that shorting and they only brought AMLN down to 19? hmmm.

[jiesen]

cool, glad to hear I got something going for me, technically.